이수현 교수의 진료시간표

이수현 교수의 상세정보

• 2010 .03  ~  2012 .08  :  성균관대학교 대학원 의학박사 졸업
• 2000 .03  ~  2004 .02  :  연세대학교 의과대학 졸업
• 1998 .03  ~  2000 .02  :  서울대학교 사회학과 대학원 박사수료
• 1995 .03  ~  1997 .02  :  서울대학교 사회학과 대학원 석사졸업

• 2004 .03  ~  2009 .02  :  신촌세브란스병원 인턴, 내과 전공의
• 2009 .03  ~  2010 .02  :  삼성서울병원 혈액종양내과 전임의
• 2010 .03  ~  2011 .02  :  신촌세브란스병원 종양내과 임상연구조교수
• 2011 .03  ~  2014 .02  :  신촌세브란스병원 종양내과 임상조교수
• 2014 .03  ~  2019 .02  :  제약회사의사 (Pfizer and Celgene)

•  ~   :  미국임상종양학회 회원
•  ~   :  미국 암 연구학회 회원
•  ~   :  유럽종양내과학회 회원
•  ~   :  대한암학회, 대한종양내과학회 회원
•  ~   :  대한항암요법 연구회 국제협력위원, IRB 위원, QA 위원

•  ~   :  (사) 한국이주민건강협회 의료심사위원

• [SCI] (Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea)
• [SCI] (Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures)
• [SCI] (Effects of a Mindfulness-Based Stress Reduction Program on the Physical and Psychological Status and Quality of Life in Patients With Metastatic Breast Cancer)
• [SCI] (A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy)
• [SCI] (Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results)
• [SCI] (Statins affect ETS-1-overexpressing triple-negative breast cancer cells by restroring DUSP4 deficiency)
• [SCI] (Prognostic Value of Axillary Nodal Ratio After Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide (AC) Followed by Docetaxel (DOC): A Multicenter Retrospective Cohort Study)
• [SCI] (Characteristics of venous thromboembolism in pancreatic adenocarcinoma in East asian ethnics: a large population-based observational study)
• [SCI] (Quality of life in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine chemotherapy: results from phase lll, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02))
• [SCI] (Prediction of short- and long-term survival for advanced cancer patients after ICU admission)
• [SCI] (Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevelance, clinicopathological features and prognostic implication)
• [SCI] (Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with confirmal bone system: a preliminary report)
• [SCI] (Trends in receiving chemotherapy for advanced cancer patients at the end of life)
• [SCI] (Phase ll study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG) GY 10-10)
• [SCI] (Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib)
• [SCI] (Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma)
• [SCI] (Case series of different onset of skin metastasis according to the breast cancer subtype)
• [SCI] (Overexpression of catalase, ROS scavenge enzyme, is related with good prognosis in TNBC)
• [SCI] (Craniofacial osteosarcoma : single institutional experience in Korea)
• [SCI] (Radiation recall dermatitis induced by Trastuzumab)
• [SCI] (Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool)
• [SCI] (Muticentre phase ll trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905))
• [SCI] (Phase lll, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after chieving disease control with six cycles of gemcitab 1. plus paclitaxel as first-line chemotherapy: KCSG-BR07-02)
• [SCI] (Prognostic impact of FOXP3 expression in triple-negative breast cancer)
• [SCI] (Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors)
• [SCI] (FOXP3 expression in related to high grade Ki-67 index and poor prognosis in lymph node-positive breast cancer patients)
• [SCI] (Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer)
• [SCI] (S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial)
• [SCI] (Psychosocial impact of cancer patients on their family members)
• [SCI] (Successful Sirolimus treatment of multiple visceral Kaposi’s sarcoma in a renal allograft patient)
• [SCI] (Statins and the risk of gastric cancer in diabetes patients)
• [SCI] (Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma)
• [SCI] (Prediction of outcomes of for patients with brain parenchymal metastases from breast (BC): a new BC-specific prognostic model and a nomogram)
• [SCI] (Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study)
• [SCI] (Overexpression of calss lll beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy)
• [SCI] (Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations)

• 한쪽가슴으로 사랑하기

최종수정일 : 2019.08.20